medwireNews: Mineralocorticoid receptor antagonists (MRAs) reduce the risk for heart failure (HF) hospitalization or cardiovascular death in patients with HF, regardless of their ejection fraction phenotype, suggests a patient-level meta-analysis of four randomized controlled trials.
20-09-2024 | Heart Failure | Editor's Choice | News